If this message is not displayed correctly, click here.
NDT-Educational@ENP Newsletter Issue 2 - March 2019
EDITOR IN CHIEF: Davide Bolignano EDITORIAL BOARD: click here for the complete list NEWSLETTER DESIGN: Francesca Trebelli
Summary Reports from 55th ERA-EDTA Congress The conundrum of treating gout in patients with CKD presented by Jakub Závada ![]() Gout is the most common inflammatory arthritis in the general population of the Western world, with an estimated prevalence ranging from 1.4%, in the UK and Germany, to 3.9% in the USA. However, in patients with chronic kidney disease (CKD), the prevalence is much higher, reaching 24% in those with CKD stages 3-4 in Germany, and nearly 30% in CKD stage 4 patients in the USA. As many as 31% of these patients are not treated at all, while nearly half of them (47%) are undertreated. Furthermore, patients with gout have much higher risk of having CKD.
Congress Presentation This Congress talk has been presented by Jakub Zàvada during the 55th ERA-EDTA Congress in Copenhagen, Denmark. ![]()
New paradigms of the kidney – Vascular-bone axis in CKD Presented by Klaus Olgaard ![]() There has been no significant progress in the therapeutic management of chronic kidney disease (CKD)-mineral bone disorders (MBD) since the introduction of KDIGO CKD-MBD Guidelines in 2009, hence, an urgent need exists to better understand the pathophysiology of this condition. The new paradigm on the parathyroid-kidney–vascular-bone axis has revealed that CKD-MBD consists of a fascinating number of complex disturbances in the tissue cross-talk between these different organs in uraemia.
Congress Presentation This Congress talk has been presented by Klaus Olgaard during the 55th ERA-EDTA Congress in Copenhagen, Denmark. ![]()
References Read this selection of articles about the two summary report fields. ![]()
ERA-EDTA Dialogues ![]() A puzzling case for the transplantologist by Ana Carina Ferreira Therapeutic approach in multi-resistant FSGS: your opinion matters! by Francesco Pesce ![]() ![]() Is SGLT-2 inhibition being the dawn of a new era in preventing CKD progression in nondiabetic patients? by Evangelia Ntounousi
The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the EU General Data Protection Regulation (2016/679). |